Placebo-Controlled Single and Multiple Ascending Dose Study of LY4006895 in Healthy Volunteers and Early Symptomatic Alzheimer's Disease

Phase 1, randomised, double-blind trial of LY4006895 in Alzheimer's disease (AD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Treatment-emergent adverse events, serious adverse events, and discontinuations due to adverse events related to LY4006895 and Reported adverse events summary. Planned start Jun 2026; status: not yet recruiting.